Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Lamb

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Pathology|November 21, 2007
Prostate cancer: the new evidence base for diagnosis and treatmentDavid S Lamb, David Slaney, Robin Smart, et al.
Cancer|August 20, 2009
Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?James W Denham, Allison Steigler, Chantelle Wilcox, et al.
Pathology|May 5, 2010
Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end pointBrett Delahunt, David S Lamb, John R Srigley, et al.
Anticancer Research|December 1, 2017
Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical FailureDavid S Lamb, Sven Sondhauss, Jonathan C Dunne, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2010
A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trialDavid S Lamb, James W Denham, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
Cancer|April 21, 2015
The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancerLaurien M Buffart, Robert U Newton, Mai J Chinapaw, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?James W Denham, Allison Steigler, Mahesh Kumar, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Pathology|November 21, 2007
Prostate cancer: the new evidence base for diagnosis and treatmentDavid S Lamb, David Slaney, Robin Smart, et al.
Cancer|August 20, 2009
Why are pretreatment prostate-specific antigen levels and biochemical recurrence poor predictors of prostate cancer survival?James W Denham, Allison Steigler, Chantelle Wilcox, et al.
Pathology|May 5, 2010
Gleason scoring: a comparison of classical and modified (international society of urological pathology) criteria using nadir PSA as a clinical end pointBrett Delahunt, David S Lamb, John R Srigley, et al.
Anticancer Research|December 1, 2017
Proteins Annexin A2 and PSA in Prostate Cancer Biopsies Do Not Predict Biochemical FailureDavid S Lamb, Sven Sondhauss, Jonathan C Dunne, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2010
A comparison of the prognostic value of early PSA test-based variables following external beam radiotherapy, with or without preceding androgen deprivation: analysis of data from the TROG 96.01 randomized trialDavid S Lamb, James W Denham, David Joseph, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2013
Paradoxical metastatic progression following 3 months of neo-adjuvant androgen suppression in the TROG 96.01 trial for men with locally advanced prostate cancerJames W Denham, Allison Steigler, Keen-Hun Tai, et al.
Prostate Cancer|January 16, 2013
Risk Stratification after Biochemical Failure following Curative Treatment of Locally Advanced Prostate Cancer: Data from the TROG 96.01 TrialAllison Steigler, James W Denham, David S Lamb, et al.
Cancer|April 21, 2015
The effect, moderators, and mediators of resistance and aerobic exercise on health-related quality of life in older long-term survivors of prostate cancerLaurien M Buffart, Robert U Newton, Mai J Chinapaw, et al.
The Lancet. Oncology|March 29, 2011
Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trialJames W Denham, Allison Steigler, David S Lamb, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2009
Measuring time to biochemical failure in the TROG 96.01 trial: when should the clock start ticking?James W Denham, Allison Steigler, Mahesh Kumar, et al.
Pageof 5